Crizotinib induces PUMA-dependent apoptosis in colon cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• MET and ALK oncogenic alterations drive various cancers.
• Crizotinib is an approved dual MET/ALK inhibitor used in non-small cell lung carcinoma and other malignancies.
• The precise mechanisms by which crizotinib induces cancer cell apoptosis remain incompletely understood.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying crizotinib-induced apoptosis in colon cancer cells.
• To investigate the role of the BH3-only protein PUMA in mediating crizotinib's apoptotic effects.
• To explore the interplay between p53, PUMA, and MET signaling in response to crizotinib.

Main Methods:

• Utilized colon cancer cell lines with wild-type and deficient p53.
• Performed MET knockdown experiments.
• Assessed apoptosis induction, protein stabilization (p53), and DNA damage response.
• Evaluated crizotinib's synergistic effects with gefitinib and sorafenib.
• Tested therapeutic responses in crizotinib-treated xenograft models.

Main Results:

• Crizotinib induces apoptosis in colon cancer cells primarily through the BH3-only protein PUMA.
• In p53-proficient cells, crizotinib triggers PUMA and Bim induction, p53 stabilization, and DNA damage.
• PUMA or p53 deficiency, but not Bim deficiency, abrogates crizotinib-induced apoptosis.
• MET knockdown selectively induces PUMA, independent of p53 or Bim.
• Crizotinib demonstrates PUMA-dependent apoptosis in p53-deficient cells and synergizes with other inhibitors.
• PUMA deficiency impairs apoptosis and therapeutic efficacy in vivo.

Conclusions:

• PUMA is a critical mediator of colon cancer cell apoptosis induced by crizotinib.
• The findings suggest cell-type-specific mechanisms of oncogenic addiction to MET/ALK signaling.
• These results have significant implications for the clinical development of crizotinib.